DOMINICA protocol: A study of benralizumab for severe eosinophilic asthma in children

Pediatric Allergy and Immunology 2026 Open access

Read full text
Authors: Theresa W. Guilbert, Maria L. Jison, Lena Börjesson Sjö, Viktoría Werkström, Hanna Grindebacke, Tomasz Durżyński, Aadarsh Lal, Jonathan Grigg
DOI: 10.1111/pai.70272
Cited by: 1
References: 10

Abstract

The treatment of severe asthma in pediatric patients presents significant challenges that need to be addressed. Asthma is defined as “severe” if it does not respond to a high dose of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) treatment, or if it worsens when the dose is reduced.1 Approximately 3% of children and adolescents with asthma in Europe have severe asthma.2 Patients with severe eosinophilic asthma (SEA) have increased levels of blood eosinophils and airway inflammation, which result in greater asthma exacerbation rates when compared to patients with a blood eosinophil count of

Fields of Study & Subjects

Asthma and respiratory diseases Eosinophilic Esophagitis Eosinophilic Disorders and Syndromes

Publication details

Journal / source
Pediatric Allergy and Immunology
Publisher
Wiley
Volume
37
Issue
3
Pages
e70272–e70272
Publication date
27 February 2026
Language
EN